The problems of clinical trials and registries in rare diseases

Respiratory Medicine

Volumn 104, Issue SUPPL. 1, 2010, Pages

  Luisetti, Maurizio ^a   Campo, Ilaria ^a   Scabini, Roberta ^a   Zorzetto, Michele ^a   Kadija, Zamir ^a   Mariani, Francesca ^a   Ferrarotti, Ilaria ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aerosol delivery of drugs; Alpha1 antitrypsin; Alpha1 antitrypsin deficiency; GM CSF; Pulmonary alveolar proteinosis; Rare diseases

Indexed keywords

ALPHA 1 ANTITRYPSIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LUNG SURFACTANT;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC LIVER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE REGISTRY; ENZYME REPLACEMENT; HUMAN; LUNG ALVEOLUS PROTEINOSIS; LUNG EMPHYSEMA; LUNG LAVAGE; PRIORITY JOURNAL; RARE DISEASE;

ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIALS AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; PATIENT SELECTION; PULMONARY ALVEOLAR PROTEINOSIS; RARE DISEASES; REGISTRIES;

EID: 77953019771     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.03.016     Document Type: Article

References (12)

1. de Serres F.J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency. Summary of an analysis of published genetic epidemiology surveys. Chest 122 (2002) 1818-1829
2. Alpha1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 75 (1997) 397-415
3. Stockley R.A., Luisetti M., Miravitlles M., Piitulainen E., and Fernandez P. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Eur Respir J 29 (2007) 582-586
4. Bakker M.E., Stolk J., Putter H., et al. Variability in densitometric assessment of pulmonary emphysema with computed tomography. Invest Radiol 40 (2005) 777-783
5. Dirksen A., Dijkman J.H., Madsen F., et al. A randomized clinical trial of alpha1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160 (1999) 1468-1472
6. Dirksen A., Piitulainen E., Parr D.G., et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency. Eur Respir J 33 (2009) 1345-1353
7. Trapnell B.C., Whitsett J.A., and Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 349 (2003) 2527-2539
8. Ramirez R.J., Schultz R.B., and Dutton R.E. Pulmonary alveolar proteinosis: a new technique and rationale for treatment. Arch Intern Med 112 (1963) 419-431
9. Kitamura T., Nakata K., Watanabe J., et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190 (1999) 875-880
10. Inoue Y., Trapnell B.C., Tazawa R., et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 177 (2008) 752-762
11. Beccaria M., Luisetti M., Rodi G., et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 23 (2004) 526-531
12. Clinical Trials.gov. Whole lung lavage (WLL)/inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis (PAP). http://www.clinicaltrial.gov/ct2/show/NCT00901511 [accessed 05.02.10]